Physician profile
M Bashar Atai
NPI 1538111075
$927.28
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $89.71 · 2021: $48.31 · 2022: $250 · 2023: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.05 | 2022-2023 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $123.49 | 2019-2022 | |
| Novo Nordisk INC | $81.38 | 2019-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $74.13 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $64.48 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $62.29 | 2019-2020 | |
| Pfizer INC. | $59.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $50.71 | 2020-2023 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $43.06 | 2019 | |
| Daiichi Sankyo INC. | $29.89 | 2023 | Injectafer |
| Edwards Lifesciences Corporation | $28.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.57 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.32 | 2023 | Trulance, Xifaxan |
| Lilly USA, LLC | $12.81 | 2023 | Emgality, Jardiance |
| Abbott Laboratories | $12.75 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Bashar Atai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.